Nat Clin Pract Oncol. 2008;5(9):531-542. The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co ...

WATCH: Understanding the hormone therapy drug Tamoxifen. Tamoxifen is a type of hormone therapy drug used to treat breast cancer. It is also used to prevent breast cancer among women who are at ...

Women who received an LHRH agonist plus tamoxifen had a reduced ... suggest that adjuvant LHRH agonist therapy could enhance the response of hormone-sensitive, early-stage breast cancer to ...

Dr Nidhan Biswas, the lead investigator from NIBMG, emphasised how this study moves India closer to personalised cancer care. “By identifying patients at high risk of drug resistance early, we can ...

breast cancer develop resistance to hormone treatment, and a potential new approach to overcome the problem. Around 80% of breast cancers are ER+ and are treated with anti-oestrogen therapies such as ...

The program of therapy prescribed for you depends on several factors including: tumor size, lymph node status, cell type, hormone receptor tests, cell growth patterns ... One of the most common drugs ...

Doctors think that tamoxifen stops estrogen from attaching ... It blocks estrogen from working on cancer cells that are sensitive to the hormone. It blocks estrogen from acting on cells that ...

well-controlled clinical studies have established the efficacy and safety of initial adjuvant therapy with letrozole or anastrozole versus the previous standard of 5 years of adjuvant tamoxifen ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative ...